Biopharma and pharmaceutical laboratories in Pakistan operate under continuous regulatory pressure because laboratory data directly supports product quality, patient safety, and market authorization. Inspections by DRAP and other oversight bodies focus less on analytical outcomes and more on how data is generated, controlled, reviewed, and preserved. This page explains what regulators actually expect and why laboratories often experience high inspection risk even when results meet specifications.
During GMP and DRAP inspections, the central question is not:
“Did this analyst perform the test correctly?”
but rather:
“Does this laboratory have a controlled system that consistently produces reliable and defensible data?”
Inspectors evaluate laboratories as data-generation systems, looking for structural weaknesses rather than isolated errors.
Regulatory expectations align with data integrity principles that require data to be:
Paper worksheets, Excel calculations, and disconnected instrument systems frequently fail to meet these principles under inspection scrutiny.
Inspectors expect laboratories to demonstrate:
Any break in this chain—such as missing raw data or unclear approvals is treated as a critical observation, regardless of result correctness.
Regulators closely examine:
Undocumented or poorly controlled method changes are viewed as serious GMP violations.
DRAP and GMP inspectors verify that:
If instrument status cannot be confirmed at the time of analysis, the data is considered non-defensible.
Inspectors assess whether:
Informal reviews, verbal approvals, or undocumented changes are treated as systemic governance failures.
Results were reviewed by authorized personnel
QA approvals were documented and justified
Corrections and reprocessing were transparently recorded
Pharma laboratories must retain and retrieve:
Inability to retrieve complete data sets during inspection raises concerns about long-term data governance.
Stability study data
Validation and verification records
Historical batch and development data
For biopharma and pharmaceutical laboratories in Pakistan, regulatory pressure centers on data integrity, traceability, and controlled governance. Inspectors focus more on process control and documentation discipline than on individual test values. Without structured systems, laboratories remain vulnerable during GMP and DRAP inspections.